Veneto
In Veneto region 72,8% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 72 cases of cervicocarcinoma and 31 related deaths and thus results to be cos...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2008-09-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1004 |
| id |
doaj-e7d49ac9c5eb44c6a5a91dff7aa1e7be |
|---|---|
| record_format |
Article |
| spelling |
doaj-e7d49ac9c5eb44c6a5a91dff7aa1e7be2020-11-25T01:57:43ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2008-09-0191S313310.7175/fe.v9i1S.1004940VenetoMaria Caterina Cavallo0Filippo Cipriani1Simone Gerzeli2Nadia Demarteau3Alessia Marocco4Francesco Bamfi5Università Bocconi, MilanoGlaxoSmithKline Spa, VeronaDipartimento di Statistica ed Economia Applicate L. Lenti, Università di PaviaGlaxoSmithKline Biologicals, Wavre (Belgio)GlaxoSmithKline Spa, VeronaGlaxoSmithKline Spa, VeronaIn Veneto region 72,8% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 72 cases of cervicocarcinoma and 31 related deaths and thus results to be cost-effective (29.052 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 67 cancer cases and 28 deaths could be prevented, with a very similar cost-effectiveness ratio. In Veneto region, the net cost for woman vaccinated is 184 € for the single cohort and 188 € for the multiple cohort.https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1004venetohpv vaccinationeconomic & clinical impact |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Maria Caterina Cavallo Filippo Cipriani Simone Gerzeli Nadia Demarteau Alessia Marocco Francesco Bamfi |
| spellingShingle |
Maria Caterina Cavallo Filippo Cipriani Simone Gerzeli Nadia Demarteau Alessia Marocco Francesco Bamfi Veneto Farmeconomia: Health Economics and Therapeutic Pathways veneto hpv vaccination economic & clinical impact |
| author_facet |
Maria Caterina Cavallo Filippo Cipriani Simone Gerzeli Nadia Demarteau Alessia Marocco Francesco Bamfi |
| author_sort |
Maria Caterina Cavallo |
| title |
Veneto |
| title_short |
Veneto |
| title_full |
Veneto |
| title_fullStr |
Veneto |
| title_full_unstemmed |
Veneto |
| title_sort |
veneto |
| publisher |
SEEd Medical Publishers |
| series |
Farmeconomia: Health Economics and Therapeutic Pathways |
| issn |
2240-256X |
| publishDate |
2008-09-01 |
| description |
In Veneto region 72,8% of women (aged 25-64) are screened regularly, meaning every 3 years.
Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 72 cases of cervicocarcinoma and 31 related deaths and thus results to be cost-effective (29.052 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 67 cancer cases and 28 deaths could be prevented, with a very similar cost-effectiveness ratio. In Veneto region, the net cost for woman vaccinated is 184 € for the single cohort and 188 € for the multiple cohort. |
| topic |
veneto hpv vaccination economic & clinical impact |
| url |
https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1004 |
| work_keys_str_mv |
AT mariacaterinacavallo veneto AT filippocipriani veneto AT simonegerzeli veneto AT nadiademarteau veneto AT alessiamarocco veneto AT francescobamfi veneto |
| _version_ |
1724972944505962496 |